EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease
Maria K. Angelopoulou(Laiko General Hospital of Athens), Gerassimos A. Pangalis(Athens Medical Center), Constantinos Papavassiliou(Hygeia Hospital), Theodoros P. Vassilakopoulos(National and Kapodistrian University of Athens), Marina P. Siakantaris(National and Kapodistrian University of Athens), Christos Kittas(National and Kapodistrian University of Athens), Flora N. Kontopidou(Laiko General Hospital of Athens), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center)
Cited by 21
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859